bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 3.32M -63.7% |
| Revenue (ttm) | 5.90M -23.2% |
| Net Income | -15.19M |
| EPS | -59.70 |
| Shares Out | 539.86K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,549 |
| Open | 6.56 |
| Previous Close | 6.56 |
| Day's Range | 6.07 - 6.87 |
| 52-Week Range | 4.56 - 80.70 |
| Beta | -1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cance... [Read more]
Financial Performance
In 2025, bioAffinity Technologies's revenue was $6.16 million, a decrease of -34.18% compared to the previous year's $9.36 million. Losses were -$14.91 million, 64.9% more than in 2024.
Financial StatementsNews
BioAffinity, AvMEDICAL deliver joint exhibition of CyPath Lung
bioAffinity Technologies (BIAF) is taking significant steps toward bringing its lung cancer test to the veterans who need it. This week, bioAffinity and its federal healthcare distribution partner AvM...
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity and AvMEDICAL jointly presented CyPath Lung for the first time under their new distribution agreement at NAVREF 2026 Annual Conference.
bioAffinity Technologies Proxy statement: Proxy filing
bioAffinity Technologies filed a proxy statement on September 29, 2026, providing details for shareholder voting and corporate governance matters.
BioAffinity to present clinical, veteran-focused data on CyPath Lung
bioAffinity Technologies (BIAF) announced it is presenting two posters highlighting its noninvasive lung cancer diagnostic, CyPath Lung, in clinical practice and ongoing research evaluating the techno...
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
bioAffinity Technologies Inc trading resumes
12:31 EDT bioAffinity Technologies (BIAF) Inc trading resumes
bioAffinity Technologies Inc trading halted, volatility trading pause
12:26 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause
BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung
bioAffinity Technologies (BIAF) announced that the Hong Kong Intellectual Property Department has granted a patent for the Company’s proprietary platform technology for predicting the likelihood of lu...
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.
bioAffinity Technologies Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The conference showcased advances in noninvasive diagnostics, with a focus on early lung cancer detection. CyPath Lung demonstrated strong clinical performance and rapid adoption, with plans to expand into asthma and COPD diagnostics.
BioAffinity Technologies regains compliance with Nasdaq listing requirements
bioAffinity Technologies (BIAF) announced that it has received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with Nasdaq’s applicable listing requirement...
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.
bioAffinity Technologies Inc trading resumes
11:11 EDT bioAffinity Technologies (BIAF) Inc trading resumes
bioAffinity Technologies Inc trading halted, volatility trading pause
11:06 EDT bioAffinity Technologies (BIAF) Inc trading halted, volatility trading pause
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on September 3, 2026, providing details about a securities offering with the SEC.
Why Is Penny Stock BioAffinity Technologies (BIAF) Up Today?
BioAffinity Technologies stock was up on Tuesday after the company said it’s advancing its CyPath Lung test.
BioAffinity Technologies advances CyPath Lung for cancer survivor surveillance
bioAffinity Technologies (BIAF) is advancing the potential application of its CyPath Lung test for surveillance of lung cancer patients who have completed curative-intent treatment. Even when patients...
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment.
BioAffinity Technologies files to sell 1.71M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.71M shares of common stock. The company is not selling any…
bioAffinity Technologies Registration statement: Registration filing
bioAffinity Technologies filed a registration statement on August 27, 2026, providing details about a securities offering with the SEC.
bioAffinity Technologies Inc trading halted, news pending
19:50 EDT bioAffinity Technologies (BIAF) Inc trading halted, news pending
BioAffinity Technologies announces 1-for-15 reverse stock split
bioAffinity Technologies (BIAF) announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24,…
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.
BioAffinity Technologies, AvMEDICAL announce distribution agreement for CyPath
bioAffinity Technologies (BIAF) announced it has entered into a distribution agreement with AvMEDICAL. The distribution agreement is expected to strengthen bioAffinity’s ability to commercialize CyPat...